Core Insights - CONMED Corporation (CNMD) reported adjusted earnings per share (EPS) of $1.43 for Q4 2025, a 6.7% increase year over year, surpassing the Zacks Consensus Estimate by 8.6% [1] - Full-year adjusted EPS was $4.59, reflecting a 10.1% increase from the previous year, also beating the Zacks Consensus Estimate by 2.2% [2] Revenue Performance - Q4 revenues reached $373.2 million, up 7.9% year over year, exceeding the Zacks Consensus Estimate by 1.9% [3] - Full-year revenues totaled $1.37 billion, a 5.2% improvement from the prior year, aligning with the Zacks Consensus Estimate [4] Segment Analysis - Orthopedic Surgery revenues in Q4 were $157.4 million, up 13.2% year over year [5] - General Surgery revenues were $215.8 million, reflecting a 4.3% increase year over year [6] Geographical Breakdown - Domestic revenues in Q4 amounted to $206.2 million, a 1.4% increase year over year [7] - International revenues reached $167 million, up 17% year over year [9] Margin and Expense Analysis - Gross profit for Q4 increased 10.1% year over year to $218.3 million, with gross margin expanding 116 basis points to 58.5% [10] - Total operating profit was $36.6 million, down 30.2% from the previous year, with operating margin contracting 536 basis points to 9.8% [11] Financial Position - Cumulative net cash provided by operating activities at the end of Q4 2025 was $170.7 million, compared to $166.9 million a year ago [12] Future Guidance - For 2026, total reported revenues are expected to be between $1,345 million and $1,375 million, with organic CER revenues projected to grow by 4.5%-6% [13] - Adjusted EPS for 2026 is projected to be in the range of $4.30-$4.45, with the Zacks Consensus Estimate at $4.52 [13] Overall Assessment - CONMED's Q4 results showed better-than-expected performance, with strong revenue growth from both product lines and improved gross margin [14] - Management highlighted strong momentum in high-growth platforms, indicating potential for future growth [15]

Financial Data and Key Metrics Changes - Total sales for Q4 2025 were $373.2 million, a year-over-year increase of 7.9% as reported and 7.1% in constant currency [6] - Full year sales reached $1.375 billion, representing a year-over-year growth of 5.2% as reported and 5.1% in constant currency [6] - Adjusted earnings per share (EPS) for Q4 was $1.43, growing 6.7%, while full year adjusted EPS was $4.59, an increase of 10.1% [6][23] Business Line Data and Key Metrics Changes - Orthopedic sales increased by 12.1% in Q4 and 5.5% for the full year on a constant currency basis [6] - General surgery sales grew by 3.8% in Q4 and 4.7% for the full year in constant currency [6] - U.S. orthopedic sales grew 6.6%, while international orthopedic sales increased 15.7% in Q4 [17] - U.S. general surgery sales declined 0.4%, while international sales increased 14.8% in Q4 [18] Market Data and Key Metrics Changes - International sales grew 15.4% in Q4, while U.S. sales increased by 1.4% [17] - The U.S. market for general surgery faced challenges due to portfolio management and strategic focus on growth drivers [18] Company Strategy and Development Direction - The company plans to exit the gastroenterology product lines to focus on high-growth, high-margin markets such as robotic and laparoscopic surgery [7][8] - The strategy includes stabilizing and scaling operations to build a high-performance supply chain [9] - The company aims to achieve above-market growth by investing in key growth platforms and normalizing supply in sports medicine [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver sustained above-market growth through operational improvements and strategic focus [15] - The company is optimistic about the growth potential of its AirSeal and BioBrace platforms, with expectations of high single-digit to low double-digit growth rates [10][13] Other Important Information - The company suspended its dividend and approved a $150 million share repurchase authorization [15] - The leverage ratio at the end of Q4 was 2.9 times, providing flexibility for innovation and growth [24] Q&A Session Summary Question: Can you discuss the cadence for the rest of the year and any selling day differences? - Management indicated no selling day differences and expected normal seasonality for the med tech calendar [32] Question: What is the status of the CFO search? - The company is actively searching for a new CFO who will focus on shareholder value and be a strong team player [34] Question: Can you clarify the organic revenue numbers presented at the healthcare conference? - The difference in organic revenue numbers was due to final adjustments in the base numbers as the year progressed [37] Question: What drove the upside in orthopedic sales and the downside in general surgery? - The orthopedic sales benefited from a committed sales force and improved supply chain, while general surgery faced challenges due to portfolio management [41][42] Question: How will the GI business be reported going forward? - The GI business will be reported separately, reflecting its exit from the main revenue figures [54] Question: What are the growth trends for AirSeal internationally? - AirSeal continues to perform within expected growth ranges, with opportunities in both laparoscopic and robotic procedures [68]